Search
Now showing items 11-20 of 203
-
Investigational COVID-19 Convalescent Plasma - Emergency INDs
(2020-03-24)The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States from public health threats including the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to doing ... -
Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients
(2020-03-27)Background: The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak started at the end of 2019 in Wuhan, China, and spread over 100 countries. SARS-CoV-2 uses the membrane protein Angiotensin I ... -
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
(2020-03-10)Purpose: COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting ... -
Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19
(2020-03-25)Verdict: Several in vitro studies report antiviral activity of chloroquine and hydroxychloroquine against SARS-CoV-2. In vivo data, although promising, is currently limited to one study with considerable limitations. On ... -
Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis
(2020-03-30)A growing body of literature on the 2019 novel coronavirus (SARS-CoV-2) is becoming available, but a synthesis of available data has not been conducted. We performed a scoping review of currently available clinical, ... -
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
(2020-03-18)[Methods] We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2 ) ... -
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards: draft
(2020-03)In a preliminary clinical study we observed that the combination of hydroxychloroquine and azithromycin was effective active against SARS-CoV-2 by shortening the duration of viral load in Covid-19 patients. It is of paramount ... -
In vitro testing of Hydroxychloroquine and Azithromycin on SARS-CoV-2 shows synergistic effect
(2020-03)Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term ... -
Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how
(2020-04-02)Plasma provided by COVID‐19 convalescent patients may provide therapeutic relief as the number CODID‐19 cases escalate steeply world‐wide. Prior findings in various viral respiratory diseases including SARS‐CoV related ... -
Pivotal Role of Convalescent Plasma in Managing Emerging Infectious Diseases
(2020-04-02)Infectious diseases remain one of the top 10 global health threats as announced by the World Health Organization. The emergence of new pathogens for which there is no effective treatment has redrawn the attention to the ...